Retigabine structure
|
Common Name | Retigabine | ||
---|---|---|---|---|
CAS Number | 150812-12-7 | Molecular Weight | 303.331 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | 430.0±45.0 °C at 760 mmHg | |
Molecular Formula | C16H18FN3O2 | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | 213.9±28.7 °C | |
Symbol |
GHS07 |
Signal Word | Warning |
Use of RetigabineRetigabine is a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. |
Name | ezogabine |
---|---|
Synonym | More Synonyms |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 430.0±45.0 °C at 760 mmHg |
Molecular Formula | C16H18FN3O2 |
Molecular Weight | 303.331 |
Flash Point | 213.9±28.7 °C |
Exact Mass | 303.138306 |
PSA | 76.38000 |
LogP | 0.81 |
Vapour Pressure | 0.0±1.0 mmHg at 25°C |
Index of Refraction | 1.656 |
Storage condition | room temp |
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H319-H413 |
Precautionary Statements | P305 + P351 + P338 |
Hazard Codes | T,N,Xn,F,Xi |
Risk Phrases | 23-25-50/53-36-20/21/22-11 |
Safety Phrases | 45-60-61-36/37-16-26 |
RIDADR | NONH for all modes of transport |
Enhanced in vitro CA1 network activity in a sodium channel β1(C121W) subunit model of genetic epilepsy.
Epilepsia 55(4) , 601-8, (2014) A NaV β1(C121W) mouse model of human genetic epilepsy has enhanced neuronal excitability and temperature sensitivity attributed to a decreased threshold for action potential firing in the axon initial... |
|
Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel.
Expert Opin. Drug Saf. 12(6) , 847-55, (2013) Complex-partial seizures are frequently resistant to antiepileptic therapy. Two new medications with mechanisms of action novel within the antiepileptic class have recently received approval for the a... |
|
Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review.
Clin. Ther. 34(9) , 1845-56.e1, (2012) Ezogabine, also known as retigabine, is a recently approved anticonvulsant medication with a novel mechanism of action. It activates low-threshold voltage-gated potassium channels, leading to hyperpol... |
N-(2-amino-4-(4-fluorobenzylamino)-phenyl)carbamic acid ethylester |
Retigabine |
Carbamic acid, N-[2-amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]-, ethyl ester |
Trobalt |
[2-Amino-4-(4-fluoro-benzylamino)-phenyl]-carbamic acid ethyl ester |
2-Amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzene |
N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester |
Ethyl (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)carbamate |
Ezogabine |
D-23129, Ezogabine, N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester |
Ethyl {2-amino-4-[(4-fluorobenzyl)amino]phenyl}carbamate |
Potiga |
EINECS 200-835-2 |